A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Study Summary

This study evaluates the safety and tolerability of escalating doses of BP1002 (Liposomal Bcl-2 Antisense Oligodeoxynucleotide) in patients with refractory/relapsed AML. The study is designed to assess the safety profile, identify DLTs, biologically effective doses, PK, PD and potential anti-leukemic effects of BP1002 as single agent (dose escalation phase) followed by assessing BP1002 in combination with decitabine (dose expansion phase).

Conditions

Acute Myeloid Leukemia, in Relapse Acute Myeloid Leukemia Refractory

Interventions / Drugs

BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide Decitabine (in combination with BP1002)

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment48 participants

Primary Completion—

Lead SponsorBio-Path Holdings, Inc.

Data Retrieved2026-04-11 04:08:24.860894+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.